RxDoctor Payments Data

Brian Hollensworth, MD

Neurology · Mobile, ALNPI 1225121346

Payments from drug & device makers

$9,917in general payments, 2019–2025

Across 699 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$824
  • Supernus Pharmaceuticals, Inc.$799
  • Teva Pharmaceuticals USA, Inc.$730
  • Lundbeck LLC$584
  • Biogen$449
  • plus $3K from 43 others

What the payments were for

  • Speaking & faculty fees$501%
  • Food & beverage$9,86799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,917 in reported general payments places this provider in the 60th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$92,135
Medicare patients
475
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm167$137,171
IngrezzaValbenazine Tosylate15$131,790
NamzaricMemantine Hcl/Donepezil Hcl95$106,860
UbrelvyUbrogepant80$85,019
QuliptaAtogepant49$57,728
Nurtec OdtRimegepant Sulfate40$51,989
Aimovig AutoinjectorErenumab-Aooe49$39,428
AptiomEslicarbazepine Acetate22$29,598
VimpatLacosamide23$24,500
Emgality SyringeGalcanezumab-Gnlm30$22,010
Memantine Hcl606$21,439
Rivastigmine90$18,307
EliquisApixaban22$17,212
Pregabalin259$16,039
BrilintaTicagrelor23$14,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Ubrelvy, Qulipta$3,477$249,607224 claims
Neurocrine Biosciences, Inc.Ingrezza$102$131,79015 claims
PfizerNurtec Odt, Eliquis$79$69,20162 claims
UCB, Inc.Vimpat$149$24,50023 claims
AstraZenecaBrilinta$60$14,46423 claims
Upsher-smith Laboratories LLCTopiramate$41$1,614155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 neurology providers in Alabama.

Other neurology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →